- Home
- Our company
- Social impact
- Global health equity
- Advancing equitable access to care
Advancing equitable access to care
Everyone should have the opportunity to lead a healthy life. This requires that we advance equitable access to healthcare and address some of the world’s most devastating and neglected diseases.
That’s why Johnson & Johnson has long taken action to advance equitable access to our lifesaving medicines and health technologies and focuses on addressing diseases that disproportionately impact people in lower- and middle-income countries. These efforts resulted in our rise to second place in the 2022 Access to Medicine Index (ATMI), marking the sixth consecutive time Johnson & Johnson has featured among the top three performers in the Index and validating our decades-long, deliberate and focused access strategy.
Expand
Collapse
That’s why Johnson & Johnson has long taken action to advance equitable access to our lifesaving medicines and health technologies and focuses on addressing diseases that disproportionately impact people in lower- and middle-income countries. These efforts resulted in our rise to second place in the 2022 Access to Medicine Index (ATMI), marking the sixth consecutive time Johnson & Johnson has featured among the top three performers in the Index and validating our decades-long, deliberate and focused access strategy.
More than a decade of access leadership
The impact of our efforts to advance access to medicines is reflected in Johnson & Johnson’s consistent high rank in the ATMI, which evaluates global companies’ access to medicine efforts. In 2022, we rose to second place, from third in 2021, marking the sixth consecutive time we’ve ranked among the top three companies worldwide, and underscoring the enduring nature of our commitment to people impacted by devastating and neglected diseases.
Our commitment to advance access to medicines and technologies
Improving access to medicine around the world
Johnson & Johnson earned the #2 spot on the Access to Medicine Index, an important measurement of the company’s longstanding commitment to make lifesaving medicine available and accessible to those who need it most.
Champions of access
-
Through our access and pricing principles we are able to systematically plan for access across our entire portfolio, beginning at the early stages of discovery and development, ensuring that our medicines reach the people who need them most.
Jennifer TaubertExecutive Vice President, Worldwide Chairman, Pharmaceuticals, Johnson & Johnson